Valuation: Takeda Pharmaceutical Company Limited

Market Cap 9,336B 60.19B 52.13B 49.3B 44.63B 83.77B 5,774B 84.4B 588B 226B 2,927B 226B 221B P/E 2027 *
46.3x
P/E 2028 * 29.4x
Enterprise Value 13,243B 85.37B 73.95B 69.93B 63.31B 119B 8,189B 120B 834B 321B 4,152B 321B 314B EV / Sales 2027 *
2.82x
EV / Sales 2028 * 2.73x
Free-Float
99.26%
Yield 2027 *
3.49%
Yield 2028 * 3.56%
1 week+0.76%
Current year+21.41%
3 years 3,975
Extreme 3975
5,730
5 years 3,065
Extreme 3065
5,730
Manager TitleAgeSince
Chief Executive Officer 56 2024-12-31
Director of Finance/CFO 48 2024-03-31
Chief Tech/Sci/R&D Officer 47 2022-01-31
Director TitleAgeSince
Director/Board Member 60 2015-05-31
Director/Board Member 73 2018-12-31
Director/Board Member 48 2024-05-31
Change 5-day change 1-year change 3-year change Capi.($)
+0.76%+0.76%+27.97%+21.27% 59.26B
-0.19%+1.09%+51.85%+97.36% 1,015B
+0.33%-0.71%+50.62%+65.50% 642B
+0.49%+5.73%+20.88%+72.92% 463B
-0.22%+2.88%+38.48%+37.98% 353B
-0.07%+1.82%+16.57%+23.39% 265B
-0.31%+2.02%+6.15%+10.75% 254B
-1.53%-4.46%+36.90%+44.08% 206B
-1.60%-5.51%-22.30%-58.60% 191B
+0.49%-0.23%+30.00%+93.34% 182B
Average -0.08%-1.08%+25.71%+40.80% 396.69B
Weighted average by Cap. +0.40%+0.00%+34.37%+58.67%

Financials

2027 *2028 *
Net sales 4,701B 30.3B 26.25B 24.82B 22.47B 42.18B 2,907B 42.49B 296B 114B 1,474B 114B 111B 4,781B 30.82B 26.7B 25.25B 22.86B 42.9B 2,957B 43.22B 301B 116B 1,499B 116B 113B
Net income 196B 1.27B 1.1B 1.04B 939M 1.76B 122B 1.78B 12.38B 4.76B 61.61B 4.76B 4.65B 322B 2.08B 1.8B 1.7B 1.54B 2.89B 199B 2.91B 20.32B 7.82B 101B 7.81B 7.63B
Net Debt 3,907B 25.18B 21.81B 20.63B 18.68B 35.05B 2,416B 35.31B 246B 94.71B 1,225B 94.6B 92.5B 3,702B 23.87B 20.67B 19.55B 17.7B 33.22B 2,289B 33.47B 233B 89.75B 1,161B 89.65B 87.66B
Logo Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the research, development, manufacturing and global sales of a wide range of pharmaceuticals. Its main business areas are divided into six, including gastroenterology, rare diseases, plasma-derived therapies, oncology (cancer), vaccines, and neuroscience (neuropsychiatric disorders). In research and development, the Company focuses on three priority disease areas, including gastroenterology and inflammatory diseases, neuroscience, and oncology, and also focuses on plasma-derived therapies.
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
16
Last Close Price
5,847.00JPY
Average target price
6,603.31JPY
Spread / Average Target
+12.94%

Quarterly revenue - Rate of surprise

LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!